How a potential $1.2 billion cancer drug deal helps this East Bay biotech target diseases of aging


The deal is the third over the past year by the team behind Teneobio.

Previous Data Deep Dive: The gap in cancer funding
Next Mayo Clinic, Allina Health, North Memorial, Maple Grove Hospital score high on Fortune/Merative Top 100 Hospitals list